Figure 8
Responses of CRC samples with different SRS to drug therapy. (a) Multiplex immunofluorescence staining of CRC tissues in early stage and advanced stage. Yellow: CD3, far-red: CD19, red: PanCK, dark blue: DAPI. (b) The comparison of responses to anti-PD-1/ CTLA4 immunotherapy between low- and high-risk groups in the GEO cohort. (c) The comparison of responses to anti-PD-1/CTLA4 immunotherapy between low- and high-risk groups in the TCGA cohort. (d) The comparison of SRS between non-responders and responders. (e) The proportion of non-responders and responders in low- and high-SRS groups. (f) The comparison of SRS between CRC samples from chemotherapy-resistant and chemotherapy-sensitive groups. (g) The comparison of estimated IC50 of 5-FU between CRC samples from the low- and high-risk groups. (h) Top 6 potential compounds/drugs predicted to be positively or negatively associated with SRS in the PRISM database. (i) Top 6 potential compounds/drugs predicted to be positively or negatively associated with SRS in the CTRP database.
